Dr. Sulaiman Al Habib Medical Services Group announces its Interim Financial results for the Period Ending on 2026-06-30 ( Six Months )

Dr. Sulaiman Al Habib Medical Services Group reported a 12.1% year-over-year increase in net profit to SAR 662.7 million for Q2 2026, while half-year net profit for the period ending June 30, 2026, reached SAR 1.17 billion, up 1.6% from the previous year.
Quarterly revenue grew by 18.4% to SAR 4.01 billion, driven by higher patient volumes and occupancy rates in the hospital segment, which subsequently boosted pharmacy sales and HMG Solutions revenue.
EBITDA for Q2 2026 rose 21.4% to SAR 1.04 billion with a margin of 26.0%, reflecting improved operating leverage and cost absorption despite seasonal fluctuations in the preceding quarter.
Performance was influenced by the strategic expansion of the hospital network; while new facilities contributed to revenue growth, net profit margins were tempered by fixed costs associated with these sites remaining in their operational ramp-up phase.

Element List	Current Quarter	Similar quarter for previous year	%Change	Previous Quarter	% Change
Sales/Revenue	4,006.45	3,384.33	18.382	3,435.76	16.61
Gross Profit (Loss)	1,222.01	1,065.98	14.637	955.97	27.829
Operational Profit (Loss)	770.41	644.87	19.467	587.75	31.077
Net Profit (Loss) Attributable to Shareholders of the Issuer	662.66	591.02	12.121	503.29	31.665
Total Comprehensive Income Attributable to Shareholders of the Issuer	665.3	595.78	11.668	506.47	31.36
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Current Period	Similar period for previous year	%Change
Sales/Revenue	7,442.21	6,542.11	13.758
Gross Profit (Loss)	2,177.98	2,094.29	3.996
Operational Profit (Loss)	1,358.16	1,270.79	6.875
Net Profit (Loss) Attributable to Shareholders of the Issuer	1,165.95	1,148.03	1.56
Total Comprehensive Income Attributable to Shareholders of the Issuer	1,171.77	1,142.28	2.581
Total Shareholders Equity (after Deducting Minority Equity)	8,261.49	7,494.92	10.227
Profit (Loss) per Share	3.33	3.28
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Amount	Percentage of the capital (%)
Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value	-	-
All figures are in (Millions) Saudi Arabia, Riyals

Element List	Explanation
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is	The Group’s revenue increased by 18.38% in Q2 2026 to reach SAR 4,006.45 million, compared with SAR 3,384.33 million in the corresponding quarter of 2025, representing an increase of SAR 622.12 million. This increase was mainly driven by growth in revenue for both segments including hospitals and pharmacies, supported by higher patient volumes and increased occupancy rates in the hospitals segment, which positively supported higher sales in the pharmacies segment, in addition to revenue growth in the HMG Solutions segment compared with the corresponding quarter of the previous year. Revenue growth during the quarter was further supported by the continued growth and positive contribution in revenue from recently launched hospitals within the Group’s strategic network expansion. These hospitals remain in the operational ramp-up phase as they progress toward optimal utilization levels.
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is	EBITDA for Q2 2026 increased by 21.43% to SAR 1,042.14 million, compared with SAR 858.25 million in Q2 2025, with EBITDA margin reaching 26.01%. Net profit for Q2 2026 increased by 12.12% to SAR 662.66 million, compared with SAR 591.02 million in Q2 2025. The increase in net profit was mainly driven by revenue growth, higher patient volumes, and continued improved activity levels, which supported better operating leverage and cost absorption. This was partially offset by the impact of fixed costs elements associated with recently launched hospitals related to the Group’s expansion, which are currently in the ramp-up phase, with their revenue contribution expected to increase progressively as they move toward optimal utilization. Accordingly, profitability improved during Q2, while margins continue to reflect the gradual maturity profile of the expanded capacity.
The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is	Revenues increased by 16.61% in Q2 2026 compared with Q1 2026. The increase mainly reflects the recap and normalization of activity levels following the seasonal factors that affected the first quarter, together with continued growth in patient volumes and improved utilization across the Group’s network, particularly within hospitals and pharmacies.
The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is	Net profit increased by 31.67% in Q2–2026 compared to Q1–2026, driven by the recovery of revenue, despite the fact that the impact of the fixed costs associated with the recent expansions remain in the ramp-up phase.
The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is	Revenues for H1 2026 increased by 13.76% to SAR 7,442.21 million, compared with SAR 6,542.11 million in H1 2025, representing an increase of SAR 900.10 million. This increase was mainly driven by growth in revenue for both segments including hospitals and pharmacies, supported by higher patient volumes and increased occupancy rates in the hospitals segment, which positively supported higher sales in the pharmacies segment, in addition to revenue growth in HMG Solutions segment compared with the same period of the last year. Revenue growth was further supported by the continued growth and positive contribution in revenue from recently launched hospitals within the Group’s strategic expansion network. These hospitals remain in the operational ramp-up phase as they progress toward optimal utilization levels.
The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is	EBITDA for H1 2026 increased by 13.22% to SAR 1,895.66 million at EBITDA margin 25.47%, compared with SAR 1,674.30 million in H1 2025. Net profit for H1 2026 increased by 1.56% to SAR 1,165.95 million, compared with SAR 1,148.03 million in H1 2025. Despite the strong revenue increase by 13.76%, net profit growth was stabilized at 1.56%, due to the impact of fixed costs elements associated with recently launched hospitals related to the Group’s expansion, which are currently in the ramp-up phase, with their revenue contribution expected to increase progressively as they move toward optimal utilization.
Statement of the type of external auditor's report	Unmodified conclusion
Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion)	na
Reclassification of Comparison Items	na
Additional Information	na
Attached Documents	Attached Documents